XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation Expense and Employee Benefit Plans (Tables)
 6 Months Ended
Jun. 30, 2023
Compensation Related Costs [Abstract]  
Schedule of Employee and Non-Employee Stock-Based Compensation Expense
The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations (in thousands):
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2023202220232022
Cost of revenue$5,067 $4,767 $9,228 $8,627 
Research and development7,678 13,213 16,088 20,295 
Sales and marketing6,257 4,805 12,074 9,580 
General and administrative9,477 9,814 20,642 20,405 
$28,479 $32,599 $58,032 $58,907 
Schedule of Stock Option Activity
The following table summarizes the stock option activity under our stock plans during the reporting period:
 Outstanding Options
 Number of
Shares		Weighted
Average
Exercise
Price		Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
 (in thousands, except weighted average exercise price and remaining contractual life)
Balances at December 31, 2022
8,748,309 $20.70 4.6$40,532 
Exercised(208,404)7.21 
Expired(214,405)30.39 
Balances at June 30, 2023
8,325,500 20.79 4.027,715 
Vested and expected to vest at June 30, 2023
8,323,858 20.79 4.027,700 
Exercisable at June 30, 2023
8,280,499 $20.86 4.0$27,293 
The following table presents the stock activity and the total number of shares available for grant under our stock plans:
 Plan Shares Available
for Grant
Balances at December 31, 2022
28,340,641 
Added to plan8,948,255 
Granted(4,399,477)
Cancelled/Forfeited757,331 
Expired(188,617)
Balances at June 30, 2023
33,458,133 
Schedule of Stock Award Activity
A summary of our stock awards activity and related information is as follows:
Number of
Awards
Outstanding		Weighted
Average Grant
Date Fair
Value
Unvested Balance at December 31, 2022
9,549,035 $19.99 
Granted4,469,242 18.57 
Vested(2,858,763)18.31 
Forfeited(602,691)21.43 
Unvested Balance at June 30, 2023
10,556,823 $19.76